Raquel De Souza

McMaster University — Canada

Medicine · Health Sciences

19h-index1.3kcitations63works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(18), Nanoparticle-Based Drug Delivery(16), Nanoplatforms for cancer theranostics(10), Monoclonal and Polyclonal Antibodies Research(7), Cancer Research and Treatments(7)

Publications63 total

A22 INVESTIGATING THE EFFECTS OF DIET TRIGGER DISCLOSURE ON BEHAVIOUR IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH PERCEIVED GLUTEN SENSITIVITY
Journal of the Canadian Association of Gastroenterology·2024Open Access
Nova Onda Rosa Latino Americana: As eleições de 2022 da Colômbia no Twitter
Revista Política Hoje·2023Open Access
Supplementary Figures S1-S6 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Supplementary Figures S1-S6 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Supplementary Tables S1-S3 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Data from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
2023Open Access
Supplementary Materials and Methods from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Data from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
2023Open Access
Supplementary Materials and Methods from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Data from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Supplementary Tables S1-S3 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Supplementary Figure 1 from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
2023Open Access
Supplementary Figure 1 from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
2023Open Access
Data from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2023Open Access
Supplementary Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer
2023Open Access
Supplementary Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer
2023Open Access
Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer
2023Open Access
Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer
2023Open Access
POTENCIAIS CONTRIBUIÇÕES DA LÍNGUA INGLESA PARA A FORMAÇÃO INTEGRAL DE ALUNOS DO ENSINO MÉDIO INTEGRADO (EMI)
Revista Prática Docente·2023· 1 citedOpen Access
THE IMPACT OF TIMELY ACCESS TO AN ASSISTED THERAPY CENTER
XXXIX Congresso Brasileiro de Reumatologia·2022Open Access
page 1 of 4Next →

Frequent Co-authors

Christine Allen(24), Micheline Piquette‐Miller(17), David A. Jaffray(15), Payam Zahedi(12), Jinzi Zheng(11), Bart S. Hendriks(10), Daniel F. Gaddy(8), Thomas J. Wickham(8), Elena Geretti(7), Shannon C. Leonard(7), Nancy Dumont(7), Christopher W. Espelin(7), Victor Moyo(7), Helen Lee(6), Jonathan B. Fitzgerald(6), Jinzi Zheng(6), Manuela Ventura(5), Stephan G. Klinz(5), Ulrik B. Nielsen(4), U. Staub(3)